ReviewCurrent opinion in immunology2015
Synthetic biology approaches to engineer T cells.
Review in Current opinion in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control.Science advances · 2024Review
- Synthetic Cells: From Simple Bio-Inspired Modules to Sophisticated Integrated Systems.Angewandte Chemie (International ed. in English) · 2022Review
- T cell circuits that sense antigen density with an ultrasensitive threshold.Science (New York, N.Y.) · 2021Article
- A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.Journal of translational medicine · 2019Article
- Multiscale engineering of immune cells and lymphoid organs.Nature reviews. Materials · 2019Article
- An immunoproteomic approach to characterize the CAR interactome and signalosome.Science signaling · 2019Article
- Synthetic immunology: T-cell engineering and adoptive immunotherapy.Synthetic and systems biotechnology · 2018Review
- Highly Efficient and Versatile Plasmid-Based Gene Editing in Primary T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Human c-SRC kinase (CSK) overexpression makes T cells dummy.Cancer immunology, immunotherapy : CII · 2018Article
- In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.Nature nanotechnology · 2017Article
- CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.Scientific reports · 2017Article
- Multi-compartment encapsulation of communicating droplets and droplet networks in hydrogel as a model for artificial cells.Scientific reports · 2017Article
- Rapid generation of hypomorphic mutations.Nature communications · 2017Article
- Self-adjusting synthetic gene circuit for correcting insulin resistance.Nature biomedical engineering · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
There is rapidly growing interest in learning how to engineer immune cells, such as T lymphocytes, because of the potential of these engineered cells to be used for therapeutic applications such as the recognition and killing of cancer cells. At the same time, our knowhow and capability to logically engineer cellular behavior is growing rapidly with the development of synthetic biology. Here we describe how synthetic biology approaches are being used to rationally alter the behavior of T cells to optimize them for therapeutic functions. We also describe future developments that will be important in order to construct safe and precise T cell therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.